Patents by Inventor Joseph F. Foss

Joseph F. Foss has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF METHYLNALTREXONE AND RELATED COMPOUNDS TO TREAT CONSTIPATION IN CHRONIC OPIOID USERS
    Publication number: 20120277260
    Abstract: A method of preventing or treating constipation in a patient who has been chronically taking opioids, the method comprising administering a quaternary derivative of noroxymorphone in an amount sufficient to prevent or treat the side effect in the patient, but which amount would be insufficient to treat a patient with the same opioid-induced side effect who had not chronically been administered opioids.
    Type: Application
    Filed: June 26, 2012
    Publication date: November 1, 2012
    Applicant: The University of Chicago
    Inventors: Joseph F. Foss, Michael F. Roizen, Jonathan Moss, Chun-Su Yuan, William Drell
  • USE OF METHYLNALTREXONE AND RELATED COMPOUNDS TO TREAT CONSTIPATION IN CHRONIC OPIOID USERS
    Publication number: 20120190702
    Abstract: A method of preventing or treating constipation in a patient who has been chronically taking opioids, the method comprising administering a quaternary derivative of noroxymorphone in an amount sufficient to prevent or treat the side effect in the patient, but which amount would be insufficient to treat a patient with the same opioid-induced side effect who had not chronically been administered opioids.
    Type: Application
    Filed: September 12, 2011
    Publication date: July 26, 2012
    Applicant: The University of Chicago
    Inventors: Joseph F. FOSS, Michael F. ROIZEN, Jonathan MOSS, Chun-Su YUAN, William DRELL
  • USE OF METHYLNALTREXONE AND RELATED COMPOUND TO TREAT CONSTIPATION IN CHRONIC OPIOID USERS
    Publication number: 20100087472
    Abstract: A method of preventing or treating constipation in a patient who has been chronically taking opioids, the method comprising administering a quaternary derivative of noroxymorphone in an amount sufficient to prevent or treat the side effect in the patient, but which amount would be insufficient to treat a patient with the same opioid-induced side effect who had not chronically been administered opioids.
    Type: Application
    Filed: June 30, 2009
    Publication date: April 8, 2010
    Inventors: Joseph F. Foss, Michael F. Roizen, Jonathan Moss, Chun-Su Yuan, William Drell
  • USE OF METHYLNALTREXONE AND RELATED COMPOUNDS FOR TREATMENT OF GASTROINTESTINAL DYSFUNCTION INDUCED BY ENDOGENOUS OPIOIDS
    Publication number: 20090312359
    Abstract: A method of for preventing or treating gastrointestinal dysfunction and constipation caused by endogenous opioids in a patient who has been chronically taking opioids. The method comprises administering methylnaltrexone or another quaternary derivative of noroxymorphone most preferably by parenteral, intramuscular, intravenous or oral route.
    Type: Application
    Filed: December 12, 2008
    Publication date: December 17, 2009
    Inventors: Joseph F. Foss, Michael F. Roizen, Jonathan Moss, Chun-Su Yuan, William Drell
  • Oral use of methylnaltrexone and related compounds to induce laxation in chronic opioid users
    Publication number: 20040167147
    Abstract: A method of inducing Taxation in a patient who has been chronically taking opioids, the method comprising orally administering a quaternary derivative of noroxymorphone in an sufficient amount.
    Type: Application
    Filed: February 24, 2004
    Publication date: August 26, 2004
    Inventors: Joseph F. Foss, Michael F. Roizen, Jonathan Moss, Chun-Su Yuan, William Drell
  • Oral use of methylnaltrexone and related compounds to treat constipation in chronic opioid users
    Publication number: 20040167148
    Abstract: A method of treating constipation in a patient who has been chronically taking opioids, the method comprising orally administering a quaternary derivative of noroxymorphone in an amount sufficient to achieve laxation.
    Type: Application
    Filed: February 24, 2004
    Publication date: August 26, 2004
    Inventors: Joseph F. Foss, Michael F. Roizen, Jonathan Moss, Chun-Su Yuan, William Drell
  • Use of methylnaltrexone and related compounds for treatment of constipation caused by endogenous opioids
    Publication number: 20040162308
    Abstract: A method of for preventing or treating gastrointestinal dysfunction and constipation caused by endogenous opioids in a patient who has been chronically taking opioids. The method comprises administering methylnaltrexone or another quaternary derivative of noroxymorphone most preferably by parenteral, intramuscular, intravenous or oral route.
    Type: Application
    Filed: February 12, 2004
    Publication date: August 19, 2004
    Inventors: Joseph F. Foss, Michael F. Roizen, Jonathan Moss, Chun-Sun Yuan, William Drell
  • Use of methylnaltrexone and related compounds to induce laxation in chronic opioid users
    Publication number: 20040162307
    Abstract: A method of inducing laxation in a patient who has been chronically taking opioids, the method comprising administering a quaternary derivative of noroxymorphone in an amount sufficient to prevent or treat the side effect in the patient, but which amount would be insufficient to treat a patient with the same opioid-induced side effect who had not chronically been administered opioids.
    Type: Application
    Filed: February 12, 2004
    Publication date: August 19, 2004
    Inventors: Joseph F. Foss, Michael F. Roizen, Jonathan Moss, Chun-Su Yuan, William Drell
  • Use of methylnal trexone and related compounds to treat constipation in chronic opioid users
    Publication number: 20040162306
    Abstract: A method of preventing or treating constipation in a patient who has been chronically taking opioids, the method comprising administering a quaternary derivative of noroxymorphone in an amount sufficient to prevent or treat the side effect in the patient, but which amount would be insufficient to treat a patient with the same opioid-induced side effect who had not chronically been administered opioids.
    Type: Application
    Filed: February 12, 2004
    Publication date: August 19, 2004
    Inventors: Joseph F. Foss, Michael F. Roizen, Jonathan Moss, Chun-Su Yuan, William Drell
  • Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
    Publication number: 20030187010
    Abstract: A method of preventing or treating an opioid-induced side effect in a patient who has been chronically taking opioids, the method comprising administering a quaternary derivative of noroxymorphone in an amount sufficient to prevent or treat the side effect in the patient, but which amount would be insufficient to treat a patient with the same opioid-induced side effect who had not chronically been administered opioids.
    Type: Application
    Filed: February 4, 2003
    Publication date: October 2, 2003
    Inventors: Joseph F. Foss, Michael F. Roizen, Jonathan Moss, Chun-Su Yuan, William Drell
  • Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
    Publication number: 20030158220
    Abstract: A method of preventing or treating an opioid-induced side effect in a patient who has been chronically taking opioids, the method comprising administering a quaternary derivative of noroxymorphone in an amount sufficient to prevent or treat the side effect in the patient, but which amount would be insufficient to treat a patient with the same opioid-induced side effect who had not chronically been administered opioids.
    Type: Application
    Filed: February 4, 2003
    Publication date: August 21, 2003
    Inventors: Joseph F. Foss, Michael F. Roizen, Jonathan Moss, Chun-Su Yuan, William Drell
  • Use of methylnaltrexone and related compounds
    Patent number: 6608075
    Abstract: A method for preventing or treating opioid induced changes in gastrointestinal motility. The method comprises administering methylnaltrexone or another quaternary derivative of noroxymorphone to a patient prior to the administration of an opioid or after the onset of side effects induced by the administration of an opioid, wherein the methylnaltrexone or quaternary derivative is administered orally in an enterically coated form.
    Type: Grant
    Filed: May 21, 2001
    Date of Patent: August 19, 2003
    Assignees: The University of Chicago, U.R. Labs
    Inventors: Joseph F. Foss, Michael F. Roizen, Jonathan Moss, Chun-Su Yuan, William Drell
  • Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
    Patent number: 6559158
    Abstract: A method of preventing or treating an opioid-induced side effect in a patient who has been chronically taking opioids, the method comprising administering a quaternary derivative of noroxymorphone in an amount sufficient to prevent or treat the side effect in the patient, but which amount would be insufficient to treat a patient with the same opioid-induced side effect who had not chronically been administered opioids.
    Type: Grant
    Filed: September 26, 2000
    Date of Patent: May 6, 2003
    Assignees: UR Labs, Inc., The University of Chicago
    Inventors: Joseph F. Foss, Michael F. Roizen, Jonathan Moss, Chun-Su Yuan, William Drell
  • Use of methylnaltrexone and related compounds
    Publication number: 20030065003
    Abstract: A method for preventing or treating opioid induced side effects including changes in gastrointestinal motility. The method comprises administering methylnaltrexone or another quaternary derivative of noroxymorphone to a patient prior to the administration of an opioid or after the onset of side effects induced by the administration of an opioid, wherein the methylnaltrexone or quaternary derivative is administered orally in an enterically coated form.
    Type: Application
    Filed: October 23, 2002
    Publication date: April 3, 2003
    Applicant: The University of Chicago
    Inventors: Joseph F. Foss, Michael F. Roizen, Jonathan Moss, Chun-Su Yuan, William Drell
  • Use of methylnaltrexone and related compounds
    Publication number: 20020028825
    Abstract: A method for preventing or treating opioid induced side effects including changes in gastrointestinal motility. The method comprises administering methylnaltrexone or another quaternary derivative of noroxymorphone to a patient prior to the administration of an opioid or after the onset of side effects induced by the administration of an opioid, wherein the methylnaltrexone or quaternary derivative is administered orally in an enterically coated form.
    Type: Application
    Filed: May 21, 2001
    Publication date: March 7, 2002
    Inventors: Joseph F. Foss, Michael F. Roizen, Jonathan Moss, Chun-Su Yuan, William Drell
  • Use of methylnaltrexone and related compounds
    Patent number: 6274591
    Abstract: A method for preventing or treating the opioid induced side effect, inhibition of gastrointestinal motility is disclosed. The method comprises administering methylnaltrexone or another quaternary derivative of noroxymorphone to a patient prior to the administration of an opioid or after the onset of side effects induced by the administration of an opioid, wherein the methylnaltrexone or quaternary derivative is administered orally in an enterically coated form.
    Type: Grant
    Filed: July 22, 1998
    Date of Patent: August 14, 2001
    Inventors: Joseph F. Foss, Michael F. Roizen, Jonathan Moss, Chun-Su Yuan, William Drell
  • Use of methylnaltrexone and related compounds
    Patent number: 5972954
    Abstract: A method for preventing or treating opioid induced side effects including dysphoria, pruritus and urinary retention and non-opioid induced changes in gastrointestinal motility. The method comprises administering methylnaltrexone or another quaternary derivative of noroxymorphone to a patient prior to the administration of an opioid or after the onset of side effects induced by the administration of an opioid, wherein the methylnaltrexone or quaternary derivative is administered by the route selected from the group consisting of intravenous, intramuscular, transmucosal, transdermal, and oral administration, preferably administered orally in an enterically coated form.
    Type: Grant
    Filed: November 3, 1997
    Date of Patent: October 26, 1999
    Assignees: Arch Development Corporation, UR Labs, Inc.
    Inventors: Joseph F. Foss, Michael F. Roizen, Jonathan Moss, Chun-Su Yuan, William Drell